Company: ANIX
Filing Date: 2025-02-06
Form Type: DEF 14A
Source: 0001493152-25-005199
Chunk: 22

Company: Anixa Biosciences Inc
Filing Date: 2025-02-06
Form: DEF 14A
Chunk 22
---
 to the foregoing, we believe that each of the Director Nominees that is nominated for reelection is well-qualified to serve as a member of our Board due to their prior experience and work with and on our Board.

Required Vote

In the election of directors, the four persons receiving the highest number of affirmative votes cast at the Virtual Meeting will be elected.

Recommendation of the Board

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” ELECTION OF EACH OF THE NOMINEES FOR DIRECTOR.

Current Directors and Executive Officers as of the Date of this Proxy Statement

Listed below are the names of the current directors and executive officers of the Company, their ages and positions held as of the Record Date and biographies if not disclosed above:

| Name                    |     | Age |    |     | Position                           
 with the Company                   |     | Director                
 and/or                  
 Executive Officer Since |      |
| Dr. Amit Kumar          |     |     | 60 |     | Chairman of the Board              
 and                                
 Chief Executive Officer            |     |                         | 2012 |
| Dr. Arnold Baskies      |     |     | 75 |     | Director                           |     |                         | 2018 |
| Emily Gottschalk        |     |     | 64 |     | Director                           |     |                         | 2019 |
| Lewis H. Titterton, Jr. |     |     | 80 |     | Lead Independent Director          |     |                         | 2017 |
| Michael J. Catelani     |     |     | 58 |     | President, Chief Operating Officer 
 and                                
 Chief Financial Officer            |     |                         | 2016 |

| 11 |

Mr. Catelani has served as our President since April 2022, as our Chief Operating Officer since July 2017 and as our Chief Financial Officer since November 2016. Mr. Catelani is a seasoned executive with over 30 years of experience in finance and operations. From October 2012 to July 2017, he served as a contract Chief Financial Officer to a number of established privately held businesses in the biotechnology field. He served on the board of directors of PRC Clinical, a privately held clinical research organization, from January 2015 to July 2017. In July 2006, he co-founded Tacere Therapeutics, Inc., a privately held biotechnology company, and served as its Chairman, President and Chief Financial